RecruitingNCT06928909

Leukemia Adapted Protocol

Evaluating the Feasibility of an Intensity-Adapted Pediatric Acute Myeloid Leukemia Treatment Guideline in Malawi


Sponsor

Baylor College of Medicine

Enrollment

30 participants

Start Date

Jan 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

In resource-constrained settings such as Malawi, survival rates for pediatric acute myeloid leukemia (AML) are dismally low compared to high-resource environments. This disparity highlights the urgent need for feasible treatment protocols tailored to the realities of these regions where most children with cancer are treated. In 2023, after reviewing favorable clinical trials results in other resource-limited settings, the Kamuzu Central Hospital (KCH) pediatric cancer unit adopted an evidence-based intensity-adapted clinical practice guideline (CPG) developed by the International Society of Paediatric Oncology (SIOP) as its standard of care for the treatment of pediatric AML, aiming to balance curative intent with manageable toxicity. The current study is a prospective evaluation of outcomes of standard of care in Malawi using the SIOP CPG in a real-world setting. The LEAP study aims to assess the implementation of the SIOP AML guidelines at KCH in an effort to continually improve outcomes in Malawi. The study is an observational-implementation design with a composite effectiveness-implementation outcome called Implementation Success. Implementation Success combines feasibility, the ability of patients to complete all aspects of the CPG, with effectiveness, the ability to maintain historical rates of complete remission of 40% at the treatment center. This prospective cohort study will enroll children under 18 years diagnosed with de novo AML at KCH. Implementation Success will be the primary endpoint, with secondary endpoints including CPG fidelity, long-term survival, adverse events, and hematologic recovery times. Patient-reported outcomes will also be collected to assess the impact of treatment on quality of life. This will be the first prospective study of pediatric AML in sub-Saharan Africa, providing critical data on the management of AML in low-resource settings. By assessing the implementation of a context-adapted CPG, the study will contribute to the global effort to improve pediatric AML outcomes in resource-constrained environments. The findings will serve to guide practitioners in Malawi and similar settings, and the data generated will be invaluable for future clinical decisions and CPG development.


Eligibility

Max Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tracks treatment outcomes for children with a newly diagnosed blood cancer called acute myeloid leukemia (AML) in Malawi. It follows a locally adapted treatment protocol to collect data on how well patients do and to improve care in low-resource settings. **You may be eligible if...** - You are under 18 years old - You have been newly diagnosed with AML (not including certain rare subtypes) - You are beginning treatment at a hospital following the local AML treatment guidelines **You may NOT be eligible if...** - You have a specific AML subtype such as acute promyelocytic leukemia (M3), juvenile myelomonocytic leukemia, or mixed phenotype acute leukemia - You have Down syndrome (trisomy 21) - You are currently pregnant - You have already received cancer treatment (with some exceptions like steroids or hydroxyurea) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERIntensity-adapted pediatric acute myeloid treatment guidelines

This is an observational study evaluating the current standard of care AML therapy in Malawi. The therapy guideline used is an adaptation of the International Society of Paediatric Oncology (SIOP) guidelines for pediatric AML in resource-constrained centers published by the International Society of Paediatric Oncology (SIOP). It is currently the standard of care in Malawi for all patients with AML. Receipt of this therapy guideline is independent of participation in research.


Locations(1)

Kamuzu Central Hospital

Lilongwe, Lilongwe, Malawi

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06928909


Related Trials